IL1A and amyloidosis: The EMA (European Medicines Agency) and FDA (Food and Drug Administration) approved IL-1 inhibitors, anakinra and canakinumab, have been shown to be safe and effective in reducing the frequency and intensity of FMF attacks, and potentially preventing amyloidosis, the most severe complication of FMF (32–34) (Figure 1).